Skip to main navigation
Skip to search
Skip to main content
Johns Hopkins University Home
Search content at Johns Hopkins University
Home
Profiles
Research units
Research output
Surgical excision margins for primary cutaneous melanoma
Michael J. Sladden
,
Charles Balch
, David A. Barzilai
, Daniel Berg
, Anatoli Freiman
, Teenah Handiside
, Sally Hollis
, Marko B. Lens
, John F. Thompson
Research output
:
Contribution to journal
›
Review article
›
peer-review
1
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Surgical excision margins for primary cutaneous melanoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Surgical Excision
100%
Excision Margins
100%
Primary Cutaneous Melanoma
100%
Wide Local Excision
50%
Overall Survival
30%
Primary Tumor
20%
Randomized Trial
20%
Hazard Ratio
20%
Overall Mortality
20%
Relative Reduction
20%
Safety Margin
20%
95% Confidence Interval
20%
Melanoma
10%
Randomized Controlled Trial
10%
Meta-analysis
10%
Cancer Mortality
10%
MEDLINE
10%
Cochrane
10%
Embase
10%
Ongoing Trials
10%
Melanoma Cells
10%
Excision
10%
Adverse Effects
10%
Statistical Significance
10%
Long-term Survival
10%
Skin Cancer
10%
Lilac
10%
Cochrane Central Register of Controlled Trials
10%
Recurrence-free Survival
10%
Cochrane Library
10%
Cosmetic Results
10%
Small Degree
10%
Wide Margin
10%
Trial Quality
10%
Issue 3
10%
Optimal Width
10%
Statistically Significant Difference
10%
Cutaneous Melanoma
10%
Pharmacology, Toxicology and Pharmaceutical Science
Cutaneous Melanoma
100%
Melanoma Skin Cancer
100%
Overall Survival
60%
Primary Tumor
40%
Melanoma
40%
Recurrent Disease
20%
Randomized Controlled Trial
20%
Recurrence Free Survival
20%
Cancer Mortality
20%
Skin Cancer
20%
Long Term Survival
20%
Cosmetics
20%
Adverse Effect
20%
Medicine and Dentistry
Surgical Margin
100%
Melanoma Skin Cancer
100%
Wide Local Excision
50%
Overall Survival
30%
Primary Tumor
20%
Hazard Ratio
20%
Systematic Review
20%
Recurrent Disease
10%
Randomized Controlled Trial
10%
Meta-Analysis
10%
Recurrence Free Survival
10%
Melanoma Cell
10%
Cancer Mortality
10%
Long Term Survival
10%
Skin Cancer
10%
Cosmetics
10%
Melanoma
10%
Median Follow Up
10%
Adverse Effect
10%
Immunology and Microbiology
Surgical Margin
100%
Overall Survival
30%
Cochrane Library
20%
Cancer Mortality
10%
Medline
10%
Melanoma Cell
10%
Long Term Survival
10%
Recurrence Free Survival
10%
Embase
10%
Adverse Effect
10%